Tackling reproducibility in academic preclinical drug discovery.
Stephen V Frye, Michelle R Arkin, Cheryl H Arrowsmith, P Jeffrey Conn, Marcie A Glicksman, Emily A Hull-Ryde, Barbara S Slusher
Author Information
Stephen V Frye: Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7363, USA.
Michelle R Arkin: Small Molecule Discovery Center, School of Pharmacy, University of California at San Francisco, 1700 4th Street, Box 2552, San Francisco, California 94143, USA.
Cheryl H Arrowsmith: Structural Genomics Consortium, University of Toronto, Suite 700, MaRS South Tower, 101 College Street, Toronto, Ontario M5G 1L7, Canada.
P Jeffrey Conn: Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University, 1205 LH, Nashville, Tennessee 37232-0697, USA.
Marcie A Glicksman: ORIG3N, 27 Drydock Avenue, Boston, Massachusetts 02210, USA.
Emily A Hull-Ryde: Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7363, USA.
Barbara S Slusher: Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Rangos Suite 277, 855 North Wolfe Street, Baltimore, Maryland 21205, USA.
The reproducibility of biomedical research on novel drug targets has become suspect. Here, we highlight how drug discovery centres embedded in academic institutions, but with a translational imperative, can help address this reproducibility crisis.
References
Nat Rev Drug Discov. 2014 Dec;13(12):875-6
[PMID: 25435205]
